Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Liabilities and Shareholders Equity (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 254.86% to $13.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.4 million through Dec 2025, up 135.25% year-over-year, with the annual reading at $13.0 million for FY2025, 254.86% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $13.0 million at NRX Pharmaceuticals, down from $15.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $15.0 million in Q3 2025, with the low at $3.7 million in Q4 2024.